Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension

Pneumologie
H H LeuchteMarius M Hoeper

Abstract

Riociguat is the first clinically available soluble Guanylate-cyclase stimulator (sGC) and representative of a completely new class of drugs. Riociguat is approved for pulmonary arterial hypertension (PAH) and non-operable or recurrent/persistent chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, Riociguat is currently under investigation for a wider spectrum of diseases. This article focusses on its mode of action and clinical trial data. Finally, based on these data, the status of approval, as well as the costs a proposal is given how Riociguat can be integrated in the current treatment of PAH and CTEPH.

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

The New England Journal of Medicine
Hossein-Ardeschir GhofraniPATENT-1 Study Group
The New England Journal of Medicine
Hossein-Ardeschir GhofraniAuthors of CHEST-1 and PATENT-1
The New England Journal of Medicine
William R AugerPulmonary Thromboendarterectomy Program at University of California, San Diego
The New England Journal of Medicine
Emmanuel E Egom
© 2022 Meta ULC. All rights reserved